| Literature DB >> 35866796 |
Ho Yin Chung1,2, Jin Xian Huang3, Shirley Chiu Wai Chan1, Kam Ho Lee4, Helen Hoi Lun Tsang1, Chak Sing Lau1.
Abstract
We aimed to investigate the clinical, diagnostic, and imaging features of patients with late onset axial spondyloarthritis (SpA) with initial symptom manifestation aged over 45 years. Participants with axial SpA were consecutively recruited. Clinical, demographic, blood, and imaging parameters were compared between the groups with early (≤45 years) and late onset (>45 years) at a cross-sectional level. Logistic regressions were used to determine the independent associations with axial SpA with late onset. A total of 455 participants were recruited. Among them, 70 (15.4%) had late onset disease. Multivariate analyses showed that axial SpA with late onset was associated with higher C-reactive protein based ankylosing spondylitis disease activity index (ASDAS-CRP) (B = 0.10; P = .04), higher intensity of spinal inflammation as measured by maximum apparent diffusion coefficient (spinal ADC max) (B = 0.27; P = .03) and mean ADC (spinal ADC mean) (B = 0.30; P = .004), lower modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) (B = -0.12; P = .02), more tender joint count (B = 0.12; P = .02), and fewer inflammatory back pain (IBP) (OR = 0.26; P < .001). Axial SpA with late onset had higher clinical disease activity, higher intensity of spinal MRI inflammation, less radiographic damage, and more tender joint count. There was also less inflammatory back pain, which could make the diagnosis more difficult.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35866796 PMCID: PMC9302308 DOI: 10.1097/MD.0000000000029523
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Baseline characteristics of axial SpA with earlier and late onset.
| Axial SpA with early onset (age of onset ≤ 45) (n = 385) | Axial SpA with late onset (age of onset > 45) (n = 70) | ||
|---|---|---|---|
| Age (n = 455) | 41.4 ± 12.1 | 62.0 ± 7.4 | <0.001 |
| Male gender | 240/385 (62.3%) | 34/70 (48.6%) | 0.03 |
| Chinese ethnicity | 380/385 (98.7%) | 69/70 (98.6%) | 0.93 |
| Body weight (kg) (n = 401) | 66.7 ± 14.0 | 66.8 ± 13.3 | 0.61 |
| Smoking status | 105/382 (27.5%) | 14/70 (20.0%) | 0.19 |
| Regular alcohol use | 37/376 (9.8%) | 5/70 (7.1%) | 0.48 |
| Fulfilled ASAS IBP criteria | 236/382 (61.8%) | 18/70 (25.7%) | <0.001 |
| Cervical pain at onset | 45/372 (12.1%) | 14/69 (20.3%) | 0.07 |
| Thoracic pain at onset | 42/372 (11.3%) | 10/69 (14.5%) | 0.45 |
| Lumbosacral pain at onset | 153/372 (41.1%) | 38/69 (55.1%) | 0.03 |
| Buttock pain at onset | 204/372 (54.8%) | 20/69 (29.0%) | <0.001 |
| Family history of SpA | 80/371 (21.6%) | 17/69 (24.6%) | 0.57 |
| History of uveitis | 118/381 (31.0%) | 26/70 (37.1%) | 0.31 |
| Tender joint counts (n = 446) | 1.2 ± 2.6 | 2.3 ± 3.7 | 0.02 |
| Swollen joint counts (n = 447) | 0.5 ± 1.3 | 0.6 ± 1.5 | 0.71 |
| History of dactylitis | 31/381 (8.1%) | 11/70 (15.7%) | 0.05 |
| HLA-B27 positivity | 308/368 (83.7%) | 44/67 (65.7%) | 0.001 |
| Current c-DMARD therapy | 117/381 (30.7%) | 20/69 (29.0%) | 0.78 |
| BASDAI (n = 449) | 4.5 ± 2.1 | 5.1 ± 1.9 | 0.03 |
| BASFI (n = 448) | 2.7 ± 2.3 | 3.5 ± 2.4 | 0.01 |
| BAS-G (n = 446) | 4.9 ± 2.6 | 5.3 ± 2.4 | 0.17 |
| CRP (n = 448) | 1.1 ± 1.9 | 1.4 ± 3.1 | 0.36 |
| ASDAS-CRP (n = 439) | 1.9 ± 0.9 | 2.1 ± 0.9 | 0.06 |
| BASMI (n = 447) | 3.3 ± 1.7 | 4.3 ± 1.6 | <0.001 |
| Radiological AS | 214/370 (57.8%) | 31/69 (44.9%) | 0.05 |
| mSASSS (n = 423) | 10.9 ± 17.8 | 17.0 ± 17.2 | 0.01 |
| mSASSS ≥ 2 | 195/357 (54.6%) | 57/66 (84.4%) | <0.001 |
| MRI SI joints inflammation | 115/348 (33.0%) | 12/63 (19.0%) | 0.03 |
| MRI spine inflammation | 175/344 (50.9%) | 28/61 (45.9%) | 0.47 |
| MRI inflammation | 235/350 (67.1%) | 33/62 (53.2%) | 0.03 |
| SPARCC SI joints MRI score (n = 411) | 3.3 ± 6.4 | 1.2 ± 2.8 | <0.001 |
| SPARCC spine MRI score (n = 407) | 5.5 ± 7.8 | 6.2 ± 10.0 | 0.54 |
| Spine ADC max (mm2/S) (n = 92) | 1435.2 ± 316.4 | 1762.2 ± 493.8 | 0.001 |
| Spine ADC mean (mm2/S) (n = 92) | 777.1 ± 193.0 | 931.4 ± 182.7 | 0.01 |
| Fulfilled ASAS axial SpA criteria | 362/378 (95.8%) | 61/66 (92.4%) | 0.24 |
| Fulfilled ASAS axial SpA imaging criteria | 263/378 (69.6%) | 37/66 (56.1%) | 0.03 |
| Fulfilled ASAS axial SpA clinical criteria | 308/378 (81.5%) | 43/66 (65.2%) | 0.03 |
Back pain ≥ 3 months” was applied instead of “back pain ≥ 3 months and age of onset < 45 years.”
ADC = apparent diffusion coefficient, AS = Ankylosing Spodylitis, ASAS = Assessment of SpondyloArthritis international Society, ASDAS-CRP = Ankylosing Spondylitis Disease Activity Score based on CRP, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, BASFI = Bath Ankylosing Spondylitis Functional Index, BAS-G = Bath Ankylosing Spondylitis Global Score, BASMI = Bath Ankylosing Spondylitis Metrology Index, CRP = C-reactive protein, HLA = human leukocyte antigen, IBD = inflammatory back pain, MRI = magnetic resonance imaging, mSASSS = modified Stoke Ankylosing Spondylitis Spinal Score, n = number, SI = sacroiliac, SPARCC = Spondyloarthritis Research Consortium of Canada, SpA = spondyloarthritis.
Univariate and multivariate linear regressions using BASDAI and ASDAS-CRP as dependent variables.
| Univariate linear regressions | Multivariate linear regressions | |||||
|---|---|---|---|---|---|---|
| Standard coefficient (B) | Regression coefficient (95% CI) | Standard coefficient (B) | Regression coefficient (95% CI) | |||
| BASDAI | (n = 420) | |||||
| Axial SpA with late onset (n = 448) | 0.10 | 0.59 (0.07; 1.11) | 0.03 | 0.02 | 0.10 (–0.54; 0.74) | 0.76 |
| Age (n = 448) | 0.13 | 0.02 (0.01; 0.03) | 0.01 | 0.12 | 0.02 (0.001; 0.03) | 0.04 |
| Male gender (n = 448) | –0.10 | –0.40 (–0.79; –0.02) | 0.04 | –0.09 | –0.37 (–0.77; 0.30) | 0.07 |
| Chinese ethnicity (n = 448) | 0.01 | 0.20 (–1.45; 1.85) | 0.81 | |||
| Smoking status (n = 445) | 0.07 | 0.34 (–0.09; 0.78) | 0.12 | |||
| Regular alcohol use (n = 440) | 0.09 | 0.62 (–0.04; 1.29) | 0.06 | 0.11 | 0.82 (0.13; 1.51) | 0.02 |
| Family history of SpA (n = 434) | 0.01 | 0.06 (–0.40; 0.52) | 0.80 | |||
| HLA-B27 positivity (n = 428) | –0.15 | –0.77 (–1.26; –0.28) | 0.002 | –0.14 | –0.73 (–1.22; –0.23) | 0.004 |
| Current c-DMARD therapy (n = 443) | 0.01 | 0.05 (–0.36; 0.46) | 0.81 | |||
| Radiological AS (n = 432) | 0.01 | 0.02 (–0.37; 0.41) | 0.91 | |||
| ASDAS-CRP | (n = 406) | |||||
| Axial SpA with late onset (n = 438) | 0.09 | 0.21 (–0.01; 0.44) | 0.06 | 0.10 | 0.25 (0.01; 0.48) | 0.04 |
| Age (n = 438) | 0.07 | 0.004 (–0.001; 0.01) | 0.14 | |||
| Male gender (n = 438) | 0.00 | –0.001 (–0.17; 0.17) | 1.00 | |||
| Chinese ethnicity (n = 438) | –0.004 | –0.03 (–0.73; 0.67) | 0.93 | |||
| Smoking status (n = 436) | 0.10 | 0.19 (0.01; 0.38) | 0.04 | 0.07 | 0.14 (–0.07; 0.34) | 0.19 |
| Regular alcohol use (n = 431) | 0.11 | 0.34 (0.06; 0.62) | 0.02 | 0.08 | 0.26 (–0.06; 0.57) | 0.11 |
| Family history of SpA (n = 427) | –0.001 | –0.002 (–0.20; 0.20) | 0.99 | |||
| HLA-B27 positivity (n = 423) | –0.09 | –0.19 (–0.40; 0.02) | 0.08 | –0.10 | –0.21 (–0.43; 0.002) | 0.052 |
| Current c-DMARD therapy (n = 436) | 0.04 | 0.07 (–0.11; 0.25) | 0.43 | 0.13 | 0.22 (0.05; 0.40) | 0.01 |
| Radiological AS (n = 425) | 0.13 | 0.22 (0.06; 0.39) | 0.01 | |||
AS = ankylosing spondylitis, ASDAS-CRP = Ankylosing Spondylitis Disease Activity Score based on CRP, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, c-DMARD = conventional disease modifying antirheumatic drug, CI = confidence interval, HLA = human leukocyte antigen, n = number, SpA = spondyloarthritis.
Univariate and multivariate linear regressions using BASFI and BASMI as dependent variables.
| Univariate linear regressions | Multivariate linear regressions | |||||
|---|---|---|---|---|---|---|
| Standard coefficient (B) | Regression coefficient (95% CI) | Standard coefficient (B) | Regression coefficient (95% CI) | |||
| BASFI | (n = 389) | |||||
| Axial SpA with late onset (n = 447) | 0.13 | 0.82 (0.21; 1.42) | 0.01 | –0.02 | –0.12 (–0.66; 0.43) | 0.68 |
| Age (n = 447) | 0.20 | 0.03 (0.02; 0.05) | <0.001 | 0.06 | 0.01 (–0.01; 0.03) | 0.24 |
| Male gender (n = 447) | 0.01 | 0.05 (–0.39; 0.50) | 0.82 | |||
| Chinese ethnicity (n = 447) | 0.04 | 0.79 (–1.11; 2.69) | 0.41 | |||
| Body weight (n = 394) | 0.06 | 0.01 (–0.01; 0.03) | 0.20 | |||
| Smoking status (n = 444) | 0.10 | 0.54 (0.04; 1.04) | 0.03 | 0.35 | 0.19 (–0.21; 0.59) | 0.35 |
| Regular alcohol use (n = 439) | 0.11 | 0.88 (0.12; 1.64) | 0.02 | 0.03 | 0.24 (–0.36; 0.85) | 0.43 |
| Family history of SpA (n = 433) | 0.04 | 0.20 (–0.33; 0.73) | 0.47 | |||
| HLA-B27 positivity (n = 427) | –0.12 | –0.75 (–1.32; –0.18) | 0.01 | –0.05 | –0.28 (–0.70; 0.15) | 0.20 |
| BASMI (n = 442) | 0.47 | 0.63 (0.52; 0.74) | <0.001 | 0.30 | 0.41 (0.27; 0.55) | <0.001 |
| Radiological AS (n = 431) | 0.13 | 0.61 (0.17; 1.06) | 0.01 | –0.04 | –0.17 (–0.53; 0.19) | 0.36 |
| ASDAS-CRP (n = 437) | 0.67 | 1.82 (1.63; 2.02) | <0.001 | 0.58 | 1.58 (1.38; 1.78) | <0.001 |
| mSASSS (N = 416) | 0.23 | 0.03 (0.02; 0.04) | <0.001 | –0.06 | –0.01 (–0.02; 0.01) | 0.22 |
| BASMI | ||||||
| Axial SpA with late onset (n = 446) | 0.21 | 0.98 (0.54; 1.41) | <0.001 | –0.01 | –0.06 (–0.44; 0.33) | 0.77 |
| Age (n = 446) | 0.49 | 0.06 (0.05; 0.07) | <0.001 | 0.24 | 0.30 (0.02; 0.04) | <0.001 |
| Male gender (n = 446) | 0.08 | 0.27 (–0.05; 0.60) | 0.102 | |||
| Chinese ethnicity (n = 446) | 0.001 | 0.02 (–1.38; 1.41) | 0.98 | |||
| Body weight (n = 394) | –0.03 | –0.003 (–0.02; 0.01) | 0.62 | |||
| Smoking status (n = 444) | 0.14 | 0.55 (0.19; 0.92) | 0.003 | 0.004 | 0.02 (–0.27; 0.30) | 0.91 |
| Regular alcohol use (n = 439) | 0.08 | 0.48 (–0.07; 1.03) | 0.08 | –0.04 | –0.22 (–0.65; 0.21) | 0.32 |
| Family history of SpA (n = 433) | 0.02 | 0.06 (–0.33; 0.46) | 0.75 | |||
| HLA-B27 positivity (n = 426) | –0.07 | –0.31 (–0.73; 0.11) | 0.14 | |||
| ASDAS-CRP (n = 434) | 0.29 | 0.59 (0.41; 0.77) | <0.001 | 0.20 | 0.40 (0.26; 0.54) | <0.001 |
| mSASSS (n = 416) | 0.66 | 0.06 (0.06; 0.07) | <0.001 | 0.50 | 0.05 (0.04; 0.06) | <0.001 |
| Radiological AS (n = 431) | 0.32 | 1.12 (0.81; 1.43) | <0.001 | 0.14 | 0.50 (0.25; 0.75) | <0.001 |
AS = ankylosing spondylitis, ASDAS-CRP = Ankylosing Spondylitis Disease Activity Score based on CRP, BASFI = Bath Ankylosing Spondylitis Functional Index, BASMI = Bath Ankylosing Spondylitis Metrology Index, CI = confidence interval, HLA = human leukocyte antigen, mSASSS = modified Stoke Ankylosing Spondylitis Spinal Score, n = number, SpA = spondyloarthritis.
Univariate and multivariate linear regressions using SPARCC SI joints MRI score, spinal ADC max, and spinal ADC mean as dependent variables.
| Univariate linear regressions | Multivariate linear regressions | |||||
|---|---|---|---|---|---|---|
| Standard coefficient (B) | Regression coefficient (95% CI) | Standard coefficient (B) | Regression coefficient (95% CI) | |||
| SPARCC SI joints MRI score | (n = 366) | |||||
| Axial SpA with late onset (n = 410) | –0.13 | –2.07 (–3.68; –0.46) | 0.01 | 0.10 | 1.63 (–0.17; 3.43) | 0.08 |
| Age (n = 410) | –0.36 | –0.16 (–0.20; –0.12) | <0.001 | –0.41 | –0.18 (–0.23; –0.14) | <0.001 |
| Male gender (n = 410) | 0.06 | 0.73 (–0.46; 1.92) | 0.23 | |||
| Chinese ethnicity (n = 410) | 0.01 | 0.25 (–4.63; 5.13) | 0.92 | |||
| Smoking status (n = 408) | 0.002 | 0.02 (–1.32; 1.36) | 0.98 | |||
| Regular alcohol use (n = 402) | 0.03 | 0.63 (–1.25; 2.51) | 0.51 | |||
| Family history of SpA (n = 395) | –0.08 | –1.14 (–2.56; 0.28) | 0.12 | |||
| HLA–B27 positivity (n = 392) | –0.03 | –0.50 (–2.05; 1.04) | 0.52 | |||
| Radiological AS (n = 396) | –0.01 | –0.15 (–1.36; 1.07) | 0.81 | |||
| Spinal ADC max | (n = 91) | |||||
| Axial SpA with late onset (n = 91) | 0.36 | 326.96 (134.51; 519.42) | 0.001 | 0.27 | 262.94 (34.02; 491.87) | 0.03 |
| Age (n = 91) | 0.27 | 7.31 (1.79; 12.83) | 0.01 | 0.12 | 3.32 (–3.11; 9.74) | 0.31 |
| Male gender (n = 91) | 0.01 | 3.65 (–161.52; 168.81) | 0.97 | |||
| Chinese ethnicity (n = 91) | –0.03 | –71.38 (–602.11; 459.35) | 0.79 | |||
| Smoking status (n = 91) | 0.004 | 3.23 (–159.33; 165.80) | 0.97 | |||
| Regular alcohol use (n = 90) | –0.09 | -109.77 (-358.03; 138.48) | 0.38 | |||
| Family history of SpA (n = 88) | 0.17 | 164.00 (–33.62; 361.62) | 0.10 | |||
| HLA–B27 positivity (n = 87) | –0.002 | –1.77 (–238.91; 235.37) | 0.99 | |||
| Radiological AS (n = 89) | 0.07 | 57.49 (–124.95; 239.93) | 0.53 | |||
| Spinal ADC mean | (n = 91) | |||||
| Axial SpA with late onset (n = 91) | 0.31 | 160.34 (55.80; 264.89) | 0.003 | 0.30 | 156.26 (52.54; 259.99) | 0.004 |
| Age (n = 91) | 0.14 | 2.06 (–0.99; 5.11) | 0.18 | |||
| Male gender (n = 91) | –0.18 | –74.95 (–162.34; 12.43) | 0.09 | -0.16 | –68.90 (–152.77; 14.97) | 0.11 |
| Chinese ethnicity (n = 91) | 0.002 | 2.60 (–282.80; 287.99) | 0.99 | |||
| Smoking status (n = 91) | –0.01 | –3.22 (–90.60; 84.61) | 0.94 | |||
| Regular alcohol use (n = 90) | –0.07 | –45.46 (–179.56; 88.63) | 0.50 | |||
| Family history of SpA (n = 88) | –0.01 | –3.90 (–112.25; 104.44) | 0.94 | |||
| HLA–B27 positivity (n = 87) | –0.15 | –90.62 (–219.04; 37.81) | 0.16 | |||
| Radiological AS (n = 89) | 0.13 | 60.32 (–37.37; 158.01) | 0.22 | |||
ADC = apparent diffusion coefficient; AS = ankylosing spondylitis; CI = confidence interval; HLA = human leukocyte antigen; MRI = magnetic resonance imaging; n = number; SI = sacroiliac; SpA = spondyloarthritis; SPARCC = Spondyloarthritis Research Consortium of Canada.
Univariate and multivariate linear regressions using mSASSS and radiological AS as dependent variables.
| Univariate linear regressions | Multivariate linear regressions | |||||
|---|---|---|---|---|---|---|
| Standard coefficient (B) | Regression coefficient (95% CI) | Standard coefficient (B) | Regression coefficient (95% CI) | |||
| mSASSS | (n = 370) | |||||
| Axial SpA with late onset (n = 422) | 0.12 | 6.06 (1.40; 10.72) | 0.01 | –0.12 | –5.81 (–10.75; –0.87) | 0.02 |
| Age (n = 422) | 0.44 | 0.58 (0.47; 0.69) | <0.001 | 0.51 | 0.68 (0.55; 0.81) | <0.001 |
| Male gender (n = 422) | 0.24 | 8.62 (5.25; 11.99) | <0.001 | 0.20 | 7.12 (3.69; 10.54) | <0.001 |
| Chinese ethnicity (n = 422) | 0.06 | 8.49 (–5.90; 22.88) | 0.25 | |||
| Body weight (n = 383) | 0.10 | 0.13 (0.001; 0.26) | 0.05 | 0.04 | 0.06 (–0.06; 0.17) | 0.34 |
| Smoking status (n = 421) | 0.21 | 8.30 (4.54; 12.06) | <0.001 | 0.08 | 3.18 (–0.58; 6.92) | 0.097 |
| Regular alcohol use (n = 415) | 0.09 | 5.72 (–0.17; 11.62) | 0.06 | –0.03 | –1.50 (–6.90; 3.91) | 0.59 |
| Family history of SpA (n = 408) | –0.05 | –2.19 (–6.40; 2.03) | 0.31 | |||
| HLA-B27 positivity (n = 408) | 0.02 | 0.66 (–3.68; 4.99) | 0.77 | |||
| ASDAS-CRP (n = 411) | 0.12 | 2.53 (0.52; 4.55) | 0.01 | 0.07 | 1.40 (–0.38; 3.17) | 0.12 |
| Radiological AS (n = 421) | 0.31 | 10.96 (7.67; 14.24) | <0.001 | 0.22 | 8.14 (4.95; 11.34) | <0.001 |
|
|
| |||||
|
|
|
|
|
|
| |
| Radiological AS | (n = 407) | |||||
| Axial SpA with late onset (n = 439) | 0.60 | 0.36; 1.00 | 0.05 | 0.65 | 0.37; 1.16 | 0.14 |
| Age (n = 439) | 1.01 | 0.99; 1.02 | 0.45 | |||
| Male gender (n = 439) | 1.77 | 1.20; 2.60 | 0.004 | 1.25 | 0.81; 1.93 | 0.31 |
| Chinese ethnicity (n = 439) | 0.63 | 0.11; 3.46 | 0.59 | |||
| Body weight (n = 396) | 1.00 | 0.98; 1.01 | 0.55 | |||
| Smoking status (n = 437) | 2.76 | 1.73; 4.40 | <0.001 | 1.84 | 1.08; 3.14 | 0.03 |
| Regular alcohol use (n = 431) | 4.92 | 2.01; 12.00 | <0.001 | 3.43 | 1.26; 9.37 | 0.02 |
| Family history of SpA (n = 425) | 0.91 | 0.58; 1.45 | 0.70 | |||
| HLA-B27 positivity (n = 424) | 2.09 | 1.28; 3.41 | 0.003 | 2.21 | 1.31; 3.76 | 0.003 |
| ASDAS-CRP (n = 426) | 1.35 | 1.08; 1.70 | 0.01 | 1.37 | 1.07; 1.75 | 0.01 |
AS = ankylosing spondylitis; ASDAS-CRP = ankylosing spondylitis disease activity score based on CRP; CI = confidence interval; HLA = human leukocyte antigen; mSASSS = modified stoke ankylosing spondylitis spinal score; n = number; SpA = spondyloarthritis.
Univariate and multivariate linear regressions using tender joint count, IBP, and history of dactylitis as dependent variables.
| Univariate linear regressions | Multivariate linear regressions | ||||||
|---|---|---|---|---|---|---|---|
| Standard coefficient (B) | Regression coefficient (95% CI) | Standard coefficient (B) | Regression coefficient (95% CI) | ||||
| Tender joint count | (n = 414) | ||||||
| Axial SpA with late onset (n = 445) | 0.14 | 1.10 (0.38; 1.82) | 0.003 | 0.12 | 0.95 (0.19; 1.71) | 0.02 | |
| Age (n = 445) | 0.08 | 0.02 (–0.003; 0.04) | 0.10 | ||||
| Male gender (n = 445) | –0.14 | –0.78 (–1.31; –0.24) | 0.004 | –0.12 | –0.72 (–1.28; –0.17) | 0.01 | |
| Chinese ethnicity (n = 445) | 0.79 | 0.92 (–1.37; 3.21) | 0.43 | ||||
| Smoking status (n = 443) | –0.06 | –0.37 (–0.98; 0.23) | 0.23 | ||||
| Regular alcohol use (n = 438) | 0.03 | 0.28 (–0.64; 1.20) | 0.55 | ||||
| Family history of SpA (n = 433) | 0.01 | 0.08 (–0.57; 0.73) | 0.81 | ||||
| HLA-B27 positivity (n = 425) | –0.11 | –0.77 (–1.46; –0.08) | 0.03 | –0.07 | –0.49 (–1.19; 0.22) | 0.18 | |
| Current c-DMARD therapy (n = 440) | 0.08 | 0.48 (–0.09; 1.06) | 0.10 | 0.09 | 0.55 (–0.05; 1.15) | 0.07 | |
| Radiological AS (n = 431) | –0.09 | –0.49 (–1.03; 0.06) | 0.08 | –0.05 | –0.26 (–0.82; 0.30) | 0.36 | |
|
|
| ||||||
|
|
|
|
|
|
| ||
| IBP | (n = 407) | ||||||
| Axial SpA with late onset (n = 452) | 0.21 | 0.12; 0.38 | <0.001 | 0.26 | 0.13; 0.54 | <0.001 | |
| Age (n = 452) | 0.97 | 0.96; 0.99 | <0.001 | 1.00 | 0.98; 1.02 | 0.74 | |
| Male gender (n = 452) | 0.80 | 0.55; 1.18 | 0.26 | ||||
| Chinese ethnicity (n = 452) | 1.29 | 0.26; 6.45 | 0.76 | ||||
| Smoking status (n = 450) | 0.92 | 0.60; 1.41 | 0.70 | ||||
| Regular alcohol use (n = 445) | 1.16 | 0.61; 2.22 | 0.65 | ||||
| Family history of SpA (n = 439) | 1.20 | 0.76; 1.89 | 0.44 | ||||
| HLA-B27 positivity (n = 432) | 1.51 | 0.93; 2.44 | 0.097 | 1.23 | 0.73; 2.08 | 0.44 | |
| mSASSS (n = 421) | 0.99 | 0.98; 1.00 | 0.09 | 0.99 | 0.98; 1.01 | 0.21 | |
| Radiological AS (n = 437) | 1.04 | 0.71; 1.53 | 0.83 | ||||
| History of dactylitis | (n = 421) | ||||||
| Axial SpA with late onset (n = 451) | 2.11 | 1.00; 4.42 | 0.05 | 1.89 | 0.86; 4.14 | 0.11 | |
| Age (n = 451) | 1.01 | 0.99; 1.03 | 0.48 | ||||
| Male gender (n = 451) | 0.37 | 0.19; 0.71 | 0.003 | 0.47 | 0.23; 0.94 | 0.03 | |
| Smoking status (n = 449) | 0.64 | 0.29; 1.42 | 0.27 | ||||
| Regular alcohol use (n = 444) | 0.72 | 0.21; 2.43 | 0.59 | ||||
| Family history of SpA (n = 439) | 0.56 | 0.23; 1.37 | 0.21 | ||||
| HLA-B27 positivity (n = 431) | 0.44 | 0.21; 0.89 | 0.02 | 0.52 | 0.25; 1.09 | 0.09 | |
| Current c-DMARD therapy (n = 446) | 1.72 | 0.89; 3.32 | 0.11 | ||||
| Radiological AS (n = 436) | 0.53 | 0.28; 1.02 | 0.06 | 0.68 | 0.34; 1.36 | 0.27 | |
AS = ankylosing spondylitis, CI = confidence interval, c-DMARD = conventional disease modifying antirheumatic drug, HLA = human leukocyte antigen, IBP = inflammatory back pain, mSASSS = modified stoke ankylosing spondylitis spinal score, n = number, SpA = spondyloarthritis.